Myriad Genetics, Inc. MYGN, +4.48%a global leader in molecular diagnostics and personalized medicine, today announced that its Myriad Women’s Health business unit will present new data from eight studies at the 2019 Society for Maternal-Fetal Medicine (SMFM) being held Feb. 11-16, 2019 in Las Vegas, NV.
“We look forward to presenting important data from our comprehensive women’s health portfolio, including our Foresight [(R) ] Carrier Screen and Prequel Prenatal Screen(TM),” said James Goldberg, M.D., board certified maternal fetal medicine specialist, medical geneticist and chief medical officer, Myriad Women’s Health. “We are particularly excited to be sharing data that demonstrates the clinical validity of our Prequel test below a fetal fraction of four percent, which means more patients receive reliable results the first time. We believe the high accuracy of Prequel at any fetal fraction level is a key differentiator to other noninvasive prenatal screening tests on the market.”
Please visit Myriad Women’s Health at booth 401 to learn more about our leading portfolio of women’s health products. Follow Myriad on Twitter via @myriadgenetics and keep up to date with meeting news and updates by using the hashtag #SMFM19.
| Featured Research at 2019 SMFM | ||
| Product | Abstract | Poster Details (Saturday, Feb. 16) |
| Foresight(R)CarrierScreen | Detection of Copy-Number Variants in Expanded Carrier Screening Maximizes Identification of Cystic Fibrosis Carriers. | Poster: 866 |
| A Data-Driven Approach for Determining Optimal Content for Expanded Carrier Screening Panels. | Poster: 916 | |
| Clinical Utility of Expanded Carrier Screening: Results-Guided Actionability and Outcomes. | Poster: 893 | |
| Education and genetic counseling in the era of expanding genetic technology. | Poster: 876 | |
| Prequel(TM)PrenatalScreen | Clarity from discordance: Leveraging fetal fraction reduces false positives in noninvasive prenatal screening. | Poster: 915 |
| Avoiding unnecessary trade-offs: Clinical experience for a noninvasive prenatal screen with both low no-call rate and high accuracy. | Poster: 923 | |
| Leveraging whole genome sequencing in noninvasive prenatal screening: a case of Prader Willi syndrome due to uniparental disomy. | Poster: 922 | |
| Rare Adds Up: Characterization of Mosaicism in Rare Autosomal Aneuploidies via Noninvasive Prenatal Screening | Poster: 877 | |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.